NFKB1 and cancer: Therefore, we first verified the presence of NF-κB motifs in active promoters/enhancers of both hidden (PLK2) and non-canonical atypical ISGs (CCL4L2, SGK1, and FPR1) previously described to have anti-cancer functions30–33 (Fig. 5e and Supplementary Fig. 8c).